Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ACP3 | P15309 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623419 | 0.87 | SLC6A4 (0.46) | SLC6A4SRCACP3SLC6A9 | |
| SCHEMBL8624097 | 0.82 | ACP3 (0.38) | SRCACP3ALDH1A1ANPEPLAP3 | |
| SCHEMBL8622068 | 0.79 | SLC6A9 (0.48) | SLC6A4ACP3SLC6A9 | |
| SCHEMBL8621232 | 0.78 | LAP3 (0.43) | ACP3ANPEPLAP3 | |
| SCHEMBL8619819 | 0.78 | LAP3 (0.43) | ACP3ANPEPLAP3 | |
| SCHEMBL8618892 | 0.78 | LAP3 (0.43) | ACP3ANPEPLAP3 | |
| SCHEMBL8618692 | 0.77 | THRA (0.35) | ACP3 | |
| SCHEMBL8621492 | 0.76 | ACP3 (0.44) | SLC6A4ACP3SLC6A9 | |
| SCHEMBL8620195 | 0.76 | F2 (0.39) | SLC6A4ACP3SLC6A9 | |
| SCHEMBL8624044 | 0.74 | POLB (0.48) | SLC6A4SLC6A9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |